Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 546/18)
  • Patent number: 10370370
    Abstract: The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 6, 2019
    Assignee: Axovant Sciences GmbH
    Inventors: Raksha Acharya, Duane A. Burnett, Matthew Gregory Bursavich, Andrew Simon Cook, Bryce Alden Harrison, Andrew J. McRiner
  • Patent number: 10177319
    Abstract: The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 8, 2019
    Assignee: HEESUNG MATERIAL LTD.
    Inventors: Young-Seok No, Kee-Yong Kim, Hyo-Kyun Ham, Jin-Seok Choi, Dae-Hyuk Choi, Sung-Jin Eum, Joo-Dong Lee
  • Patent number: 9879025
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 30, 2018
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Patent number: 9873698
    Abstract: The present invention relates to certain spirocyclic compounds that are inhibitors of 11-? hydroxyl steroid dehydrogenase type 1 (11?HSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Colin Zhang
  • Patent number: 9650389
    Abstract: The preset invention relates to a novel 8-oxoprotoberberine derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5 containing the same as an active ingredient. The novel 8-oxoproteoberberine derivative or the pharmaceutically acceptable salt thereof according to the present invention can be useful in a pharmaceutical composition for preventing or treating diseases associated with the activity of NFAT5, particularly rheumatoid arthritis or inflammatory diseases, since it is ascertained that the derivative or a pharmaceutically acceptable salt thereof has remarkably increased oral absorption compared with known protoberberine due to an improvement in the properties thereof, and inhibits the activity of NFAT5 and the secretion of inflammatory cytokines and reduces the expression of NAFT5 in mice with rheumatoid arthritis by directly inhibiting the transcription of NFT5.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: May 16, 2017
    Assignees: Korea Research Institute of Chemical Technology, The Catholic University of Korea Industry-Academic Cooperation Foundation
    Inventors: Heeyeong Cho, Hee-Jong Lim, Ge Hyeong Lee, Woo Kyu Park, Hyeon Young Kim, Dae Young Jeong, Wan Uk Kim, Chul Soo Cho, Su Jung Park, Eun Jin Han
  • Patent number: 9458179
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic ?7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: October 4, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Matthew D. Hill, Haiquan Fang
  • Patent number: 9409919
    Abstract: The present invention relates to a process for the manufacture of N-(2-((2R,12bS)-2?-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4?-imida-zolidine]-3?-yl)ethyl)-methanesulfonamide, where in the process trimethylsilyl cyanide is used.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 9, 2016
    Assignee: VETCARE OY
    Inventors: Jonas Forsman, Oili Kallatsa
  • Patent number: 9394313
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: July 19, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Patent number: 9376447
    Abstract: Provided herein is a process for the transfer-hydrogenation of ketone analogs of members of the jervine type of Veratrum alkaloids, such as cyclopamine. Also provided herein are novel ruthenium transfer-hydrogenation catalysts.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: June 28, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Daniel G. Genov, Brian C. Austad, Brian H. White
  • Patent number: 9320725
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: April 26, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Thomas Christoph
  • Patent number: 9296749
    Abstract: The present invention relates to crystalline forms of cis-(E)-4-(3-Fluorophenyl)-2?,3?,4?,9?-tetrahydro-N,N-dimethyl-2?-(1-oxo-3-phenyl-2-propenyl)-spiro[cyclohexane-1,1?[1H]-pyrido[3,4-b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for making the crystalline forms.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 29, 2016
    Assignee: Gruenenthal GmbH
    Inventor: Michael Gruss
  • Patent number: 9186362
    Abstract: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 17, 2015
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Satish K. Srivastava, Kota V. Ramana
  • Publication number: 20150144937
    Abstract: Provided are a compound represented by the following Chemical Formula 1 for an organic optoelectronic device, an organic light emitting diode including the same, and a display device including the organic light emitting diode. The structure of Chemical Formula 1 is described in the specification. The compound for the organic photoelectric device provides an organic light emitting diode having excellent life-span characteristics due to excellent electrochemical and thermal stability and high luminous efficiency at a low driving voltage.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Moo-Jin PARK, Eun-Sun YU, Mi-Young CHAE, Byung-Ku KIM, Hyo-Ju SEO, Jae-Deuk YANG
  • Patent number: 9040172
    Abstract: The present invention describes novel indenofluorene derivatives which can preferably be employed as matrix materials for phosphorescent dopants or as electron-transport materials, in particular for use in the emission and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to polymers which comprise these compounds as structural units and to a process for the preparation of the compounds according to the invention and to electronic devices which comprise same.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: May 26, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Teresa Mujica-Fernaud, Arne Buesing, Holger Heil
  • Patent number: 9040175
    Abstract: The present invention relates to an electronic device comprising at least one organic semiconducting material according to the following formula (I): wherein R1-4 are independently selected from H, halogen, CN, substituted or unsubstituted C1-C20-alkyl or heteroalkyl, C6-C20-aryl or C5-C20-heteroaryl, C1-C20-alkoxy or C6-C20-aryloxy, Ar is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, and R5 is selected from substituted or unsubstituted C6-C20-aryl or C5-C20-heteroaryl, H, F or formula (II).
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: May 26, 2015
    Assignee: NOVALED AG
    Inventors: Omrane Fadhel, Ramona Pretsch
  • Patent number: 9035054
    Abstract: The present invention relates to the field of organic chemistry and in particular to organic free radicals used as polarizing agents in the technique of Dynamic Nuclear Polarization (DNP), which involves transferring the polarization of electron spins to the nuclei of a compound whose Nuclear Magnetic Resonance (NMR) is being observed. It concerns Dinitroxide-type Biradical polarizing agents characterized by a rigid linkage between the aminoxyl groups of said nitroxide units. This particular structure enables, at low temperatures and high fields, optimal transfer of polarization and optimal enhancement of NMR/MAS signals of the polarized nuclei of the compound studied.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: May 19, 2015
    Assignee: UNIVERSITE D'AIX-MARSEILLE
    Inventors: Oliver Ouari, Hakim Karoui, Francois Le Moigne, Paul Tordo, Robert G. Griffin, Yoh Matsuki, Thorsten Maly
  • Patent number: 9017829
    Abstract: The present invention relates to a material for an organic electroluminescent device, including a phenanthrocarbazole-based compound having a specific structure, and an organic electroluminescent device including the same. More specifically, the phenanthrocarbazole-based compound is applied as a material for a phosphorescent and fluorescent organic electroluminescent device, thereby providing an organic light emitting device with improved light emitting efficiency, luminance, thermal stability, driving voltage, lifetime and the like.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: April 28, 2015
    Assignee: Doosan Corporation
    Inventors: Jin-Seok Hong, Eun Jung Lee, Shin Han Kim, Kyoung-Soo Kim
  • Publication number: 20150105415
    Abstract: The present invention relates to the compound represented by formula (I): (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
    Type: Application
    Filed: December 17, 2014
    Publication date: April 16, 2015
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuyuki OHMOTO, Masashi KATO, Yoshifumi KAGAMIISHI, Junichiro MANAKO
  • Patent number: 9005777
    Abstract: A heterocyclic compound represented by Formula 1 below, and an organic light-emitting diode including the heterocyclic compound, and a flat display device including the organic light-emitting diode. wherein Ar1 to Ar4, X1, X2, Y1, Y2, L1, and m are defined as in the specification.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: April 14, 2015
    Assignee: Samsung Display Co., Ltd.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Jong-Hyuk Lee
  • Patent number: 8999530
    Abstract: The present invention provides a new compound and an organic electronic device using the same. The compound according to the present invention may serve as hole injection, hole transporting, electron injection and transporting, and light emitting materials and the like in an organic electronic device comprising an organic light emitting device, and the organic electronic device according to the present invention shows excellent properties in terms of efficiency, driving voltage and service life.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: April 7, 2015
    Assignee: LG Chem, Ltd.
    Inventors: Changhwan Shin, Kongkyeom Kim, Dong Hoon Lee, Jungi Jang, Minseung Chun
  • Patent number: 9000168
    Abstract: The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous extractant) capable of extracting cyclopamine, separating the extracted organic matter from the cyclopamine/extract solution, concentrating the cyclopamine/extract solution leaving a concentrated aqueous solution, contacting the concentrated aqueous solution with an organic extractant capable of selectively extracting cyclopamine from the aqueous phase, concentrating the cyclopamine-containing organic phase, providing an enriched extract containing cyclopamine, separating cyclopamine from the enriched extract using column chromatography, providing at least one fraction containing cyclopamine, and crystallizing select chromatography fractions to provide purified cyclopamine.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: April 7, 2015
    Assignee: Radient Technologies Inc.
    Inventors: Steven Splinter, Satyasagar Kadali
  • Patent number: 8999526
    Abstract: An organic photoelectric device may include an anode and a cathode configured to face each other, and an active layer between the anode and cathode, wherein the active layer includes a quinacridone derivative and a thiophene derivative having a cyanovinyl group.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: April 7, 2015
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Kwang Hee Lee, Kyu Sik Kim, Kyung Bae Park, Dong-Seok Leem, Seon Jeong Lim
  • Publication number: 20150086491
    Abstract: The invention relates to a TRPM8 modulator for achieving a cooling effect on the skin or a mucous membrane.
    Type: Application
    Filed: November 5, 2014
    Publication date: March 26, 2015
    Inventors: Thomas Subkowski, Michael Backes, Heiko Oertling, Arnold Machinek, Hubert Loges, Ulrike Simchen, Horst Surburg, Claus Bollschweiler, Jens Wittenberg, Wolfgang Siegel
  • Patent number: 8986857
    Abstract: Provided is a novel compound which can be used for a transport layer or as a host material or a light-emitting material in a light-emitting element and with which a high-performance light-emitting element can be manufactured. A dibenzo[c,g]carbazole compound in which an aryl group having 14 to 30 carbon atoms and including at least anthracene is bonded to nitrogen of a dibenzo[c,g]carbazole derivative is synthesized. By use of the dibenzo[c,g]carbazole compound, a light-emitting element having very good characteristics can be obtained.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: March 24, 2015
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Hiroki Suzuki, Satoshi Seo, Sachiko Kawakami, Tsunenori Suzuki
  • Patent number: 8986858
    Abstract: Disclosed is an organic electroluminescent device (organic EL device) that is improved in luminous efficiency, sufficiently secures driving stability, and has a simple configuration. This organic EL device comprises organic layers between an anode and a cathode piled one upon another on a substrate and at least one organic layer selected from a light-emitting layer, a hole-transporting layer, an electron-transporting layer, and a hole-blocking layer contains a carbazole compound represented by the following formula (1). In the case where the light-emitting layer of the organic electroluminescent device contains a phosphorescent dopant and a host material, it is the carbazole compound that is contained as the host material.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: March 24, 2015
    Assignee: Nippon Steel & Sumikin Chemical Co., Ltd.
    Inventors: Masashi Tada, Junya Ogawa, Takahiro Kai, Megumi Matsumoto, Yasuhisa Tsutsumi
  • Patent number: 8986852
    Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
  • Publication number: 20150065487
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Inventors: Sara Hadida-Ruah, Anna Hazlewood, Peter Grootenhuis, Fred Van Goor, Ashvani Singh, Jinglan Zhou, Jason McCartney
  • Patent number: 8962157
    Abstract: Compounds of formula I may be used in optoelectronic devices wherein R1, R2 and R4 are, independently at each occurrence, H, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or a is, independently at each occurrence, 1 or 2; b is, independently at each occurrence, an integer ranging from 0-3; c is, independently at each occurrence, an integer ranging from 0-4; Ar is independently at each occurrence, H, or heteroaryl; and at least two of Ar are heteroaryl.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 24, 2015
    Assignee: General Electric Company
    Inventors: Qing Ye, Jie Liu, Kelly Scott Chichak, Yangang Liang
  • Patent number: 8951647
    Abstract: The present invention relates to organic electroluminescent devices which comprise fluorene derivatives and spirobifluorene derivatives as matrix material for phosphorescent emitters.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: February 10, 2015
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Joachim Kaiser, Anja Gerhard, Jonas Valentin Kroeber
  • Patent number: 8952158
    Abstract: The present invention relates to the compound represented by formula (I): (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially a digestive system disease caused by stress and is superior to oral absorption.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: February 10, 2015
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kazuyuki Ohmoto, Masashi Kato, Yoshifumi Kagamiishi, Junichiro Manako
  • Publication number: 20150038490
    Abstract: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: October 20, 2014
    Publication date: February 5, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kun Liu, Shawn J. Stachel, Craig A. Coburn, Thomas G. Steele, Richard Soll, Hao Wu, Xuanjin Peng, Yaxian Cai, Xiaoxiang Du, Jian Li
  • Patent number: 8945728
    Abstract: The invention provides an organic compound incorporating a specific structure into a pyridine skeleton or a 1,3,5-triazine skeleton and adapting the molecular weight to a specific range, a composition comprising the organic compound and a solvent, organic electroluminescent element comprising a layer that is formed by using the composition, and the uses thereof.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: February 3, 2015
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Koichi Ishibashi, Hideki Gorohmaru, Wataru Shimizu, Tomomi Okamoto
  • Publication number: 20150025098
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 22, 2015
    Applicant: PFIZER INC.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • Publication number: 20150018269
    Abstract: The invention relates to compounds that can be used, in particular, as structural mimetics of proline-rich peptides and are correspondingly able to bond with proline-rich-motif binding domains (PRM domains) of proteins. The invention further relates to the use of these compounds as pharmaceutically active agents, as well as the use of the pharmaceutically active agents for the treatment of bacterial, neurodegenerative and tumor diseases.
    Type: Application
    Filed: August 24, 2012
    Publication date: January 15, 2015
    Applicants: UNIVERSITÄT ZU KÖLN, FORSCHUNGSVERBUND BERLIN E.V.
    Inventors: Ronald Kühne, Hartmut Oschkinat, Robert Opitz, Matthias Müller, Hans-Günther Schmalz, Cedric Reuter, Peter Huy
  • Publication number: 20150018347
    Abstract: The present application describes modulators of chemokine receptor activity of formula I or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Application
    Filed: October 1, 2014
    Publication date: January 15, 2015
    Inventors: T. G. Murali Dhar, John V. Duncia, Daniel S. Gardner, Weiwei Guo, John Hynes
  • Patent number: 8932734
    Abstract: Compounds comprising a 3,9-linked oligocarbazole moiety and a dibenzothiophene, dibenzofuran, dibenzoselenophene, aza-dibenzothiophene, aza-dibenzofuran, or aza-dibenzoselenophene are provided. The 3,9-linked oligocarbazole and dibenzo or aza-dibenzo moiety are separated by an aromatic spacer. The compounds may be used as non-emissive materials for phosphorescent OLEDs to provide devise having improved performance.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: January 13, 2015
    Assignee: Universal Display Corporation
    Inventor: Alexey Dyatkin
  • Patent number: 8932732
    Abstract: The present invention relates to organic electroluminescent devices, in particular blue-emitting devices, in which compounds of the formulae (1) to (4) are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: January 13, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Philipp Stoessel, Holger Heil
  • Patent number: 8927119
    Abstract: There is provided an organic compound having excellent characteristics, including excellent electron-injecting/transporting performance, hole blocking ability, and high stability in the thin-film state, for use as material of an organic electroluminescent device having high efficiency and high durability. There is also provided a high-efficient and high-durable organic electroluminescent device using the compound. The compound is represented by general formula (1) having a substituted anthracene ring structure and a pyridoindole ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and the compound is used as a constituent material of at least one organic layer.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: January 6, 2015
    Assignee: Hodogaya Chemical Co., Ltd.
    Inventors: Norimasa Yokoyama, Shuichi Hayashi, Naoaki Kabasawa, Daizou Kanda, Shigeru Kusano
  • Patent number: 8927715
    Abstract: This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: January 6, 2015
    Assignee: Vitae Pharmaceuticals, Inc.
    Inventors: David A. Claremon, Suresh B. Singh, Colin M. Tice, Yuanjie Ye, Salvacion Cacatian, Wei He, Robert Simpson, Zhenrong Xu, Wei Zhao
  • Patent number: 8921363
    Abstract: The present invention relates to a compound represented by general formula I: or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, A6, R2, R7, W, X, Y and Z are defined within. These compounds are useful for the modulation of ?-secretase enzyme activity and for the treatment of ?-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: December 30, 2014
    Assignee: Amgen Inc.
    Inventors: Ana Elena Minatti, Yuan Cheng, Wenge Zhong
  • Publication number: 20140378680
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 12, 2014
    Publication date: December 25, 2014
    Inventors: Shaomeng Wang, Shanghai Yu, Wei Sun, SanJeev Kumar, Duxin Sun, Peng Zou, Donna McEachern, Yujun Zhao
  • Publication number: 20140371456
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 18, 2014
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • Publication number: 20140371457
    Abstract: Provided is a production method for a cis-QMF, which has a low environmental burden and is industrially advantageous. Specifically provided is a production method for a cis-type 2-alkylspiro(1,3-oxathiolane-5,3?)quinuclidine hydrochloride, including: reacting a cis-trans isomer mixture of 2-alkylspiro(1,3-oxathiolane-5,3?)quinuclidine with p-nitrobenzoic acid; resolving the resultant product to produce a cis-type 2-alkylspiro(1,3-oxathiolane-5,3?)quinuclidine p-nitrobenzoate; and converting the p-nitrobenzoate into a hydrochloride.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yutaka KITAGAWA, Masao FUJITA, Kumiko OTAYA
  • Patent number: 8911886
    Abstract: A material for electroluminescent devices which comprises a compound in which a heterocyclic group having nitrogen is bonded to carbazolyl group and an organic electroluminescent device having at least one organic thin film layer which is sandwiched between the cathode and the anode and contains the above material in at least one layer, are provided. The material can provide organic electroluminescent devices emitting bluish light with a high purity of color. The organic electroluminescence device uses the material.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: December 16, 2014
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Toshihiro Iwakuma, Chishio Hosokawa, Hidetsugu Ikeda, Seiji Tomita, Takashi Arakane
  • Publication number: 20140357868
    Abstract: The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of ? ketone product and ? ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.
    Type: Application
    Filed: May 2, 2014
    Publication date: December 4, 2014
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Brian C. Austad, Andre Lescarbeau, Lin-Chen Yu
  • Publication number: 20140357617
    Abstract: The invention relates to novel heterocyclic acrylamide compounds (I), to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.
    Type: Application
    Filed: August 20, 2014
    Publication date: December 4, 2014
    Applicant: FAB PHARMA S.A.S.
    Inventors: Vincent Gerusz, Sonia Escaich, Mayalen Oxoby, Alexis Denis
  • Patent number: 8889675
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: November 18, 2014
    Assignee: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Patent number: 8889271
    Abstract: Disclosed are a novel-structural compound including a 5-membered heterocycle, an organic electronic device using the same, and a terminal thereof.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: November 18, 2014
    Assignees: Duksan High Metal Co., Ltd., Samsung Mobile Display Co., Ltd.
    Inventors: Junghwan Park, Daesung Kim, Jungcheol Park, Kiwon Kim, Jinuk Ju, Jangyeol Baek, Soungyun Mun, Yongwook Park, Hwasoon Jung, Wonsam Kim, Jihun Byun, Sungjin Park, Eunkyung Kim, Daehyuk Choi, Dongha Kim, Hansung Yu, Kwanhee Lee, Taeshick Kim, Daeyup Shin, Mikyung Kim, Dongheon Kim
  • Publication number: 20140336153
    Abstract: The present invention provides substituted pyridine derivatives of formula (I), which may be therapeutically useful as as anti-bacterial agents, more particularly FabI inhibitors. Formula (I) in which R1 to R5 and L have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage anti-bacterial agents, more particularly FabI inhibitors. The present invention also provides methods for synthesizing and administering the FabI inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 13, 2014
    Inventors: Mohamed Takhi, Subramanya Hosahalli, Sunil Kumar Panigrahi, Muni Kumar Mahadari, Chandrashekar Reddy Kottam, Noorsaadah Abd Rahman, Rohana Yusof
  • Publication number: 20140319097
    Abstract: A phenolic monomer used in the lithographic process for semiconductor fabrication, a polymer for preparing a resist under-layer comprising the same, and a resist under-layer composition comprising the same, are disclosed.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 30, 2014
    Inventors: Jeong-Sik Kim, Jae-Woo Lee, Jae-Hyun Kim